ARTELO BIOSCIENCES INC (ARTL) Stock Price & Overview
NASDAQ:ARTL • US04301G6070
The current stock price of ARTL is 4.05 USD. Today ARTL is up by 246.15%. In the past month the price decreased by -20.41%. In the past year, price decreased by -79.69%.
ARTL Key Statistics
- Market Cap
- 8.586M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -13.94
- Dividend Yield
- N/A
ARTL Stock Performance
ARTL Stock Chart
ARTL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ARTL. When comparing the yearly performance of all stocks, ARTL is a bad performer in the overall market: 96.7% of all stocks are doing better.
ARTL Earnings
ARTL Forecast & Estimates
6 analysts have analysed ARTL and the average price target is 30.6 USD. This implies a price increase of 655.56% is expected in the next year compared to the current price of 4.05.
ARTL Groups
Sector & Classification
ARTL Financial Highlights
Over the last trailing twelve months ARTL reported a non-GAAP Earnings per Share(EPS) of -13.94. The EPS increased by 23.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -292.73% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ARTL Ownership
ARTL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.65 | 951.275B | ||
| JNJ | JOHNSON & JOHNSON | 20.92 | 584.618B | ||
| MRK | MERCK & CO. INC. | 22.63 | 289.542B | ||
| PFE | PFIZER INC | 9.1 | 152.449B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.49 | 123.471B | ||
| ZTS | ZOETIS INC | 17.02 | 51.652B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.9 | 26.443B | ||
| VTRS | VIATRIS INC | 5.61 | 16.373B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.5 | 11.902B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.414B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.72B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.704B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.69 | 4.169B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARTL
Company Profile
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Company Info
IPO: 2015-10-13
ARTELO BIOSCIENCES INC
505 Lomas Santa Fe, Suite 160
Solana Beach CALIFORNIA 92037 US
CEO: Gregory D. Gorgas
Employees: 6
Phone: 18589257049
ARTELO BIOSCIENCES INC / ARTL FAQ
What does ARTELO BIOSCIENCES INC do?
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. The company is headquartered in Solana Beach, California. The company went IPO on 2015-10-13. The firm is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Can you provide the latest stock price for ARTELO BIOSCIENCES INC?
The current stock price of ARTL is 4.05 USD. The price increased by 246.15% in the last trading session.
Does ARTELO BIOSCIENCES INC pay dividends?
ARTL does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARTL stock?
ARTL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Can you provide the sector and industry classification for ARTELO BIOSCIENCES INC?
ARTELO BIOSCIENCES INC (ARTL) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for ARTELO BIOSCIENCES INC?
ARTELO BIOSCIENCES INC (ARTL) will report earnings on 2026-05-11.